drugset / Trial / NCT03992131
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific participant populations in an expansion phase (Phase 2 cohorts).
Timeline
- Start
- 2019-06-28
- Primary completion
- 2022-03-08
- Completion
- 2022-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lucitanib | Small molecule | — | Oral |
| Subject | Rucaparib | Small molecule | — | Oral |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |